TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04916730

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
Study: NCT02550496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Study: NCT03341988

Intervention type: DRUG
Group type: OTHER
Intervention: Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram
Description: To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
Study: NCT03088176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
Description: Up to 4mL administered on C1D1 intratumorally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
Description: Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150mg PO qday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg PO qday
Study: NCT02250196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Study: NCT01767025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sea water
Study: NCT00614354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-glucarate solution
Description: Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
Study: NCT01843049

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-FU+DDP)
Description: Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
Study: NCT00838045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL
Description: Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
Study: NCT04276649

Intervention type: DRUG
Intervention: Caltrate
Description: Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
Study: NCT01912599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensimed Triggerfish
Description: IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensimed Triggerfish
Description: IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure
Description: Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure
Description: Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
Study: NCT02868086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT B-scans

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT angiography
Study: NCT00648895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: nebivolol 10mg, 20mg, 40mg daily dosage, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol ER (TM)
Description: Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
Study: NCT04463485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Clamping
Description: Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
Study: NCT04202263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Topical
Description: Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placement of minocycline cream 0%
Study: NCT02199444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: The dose of Sev was 2400 mg (800 mg three times a day) in all patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00795639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan = 100 mg tablet administered orally, once daily
Study: NCT03458650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 50mg
Description: In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 100mg
Description: 100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 200mg
Description: single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
Study: NCT00795639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sitaxsentan Placebo = 1 tablet administered orally, once daily
Study: NCT00407485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02297854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg
Study: NCT03122444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: Imipramine will be given daily for 21-30 days.
Study: NCT01074996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: 40-60mg bid , days 1-14, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus Leucovorin
Description: S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
Study: NCT04631874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFF0318, Champix
Description: CDFF0318: Varenicline salt changed Champix: Varenicline tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFF0318, Champix
Description: CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
Study: NCT03542409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Perfusion Scan
Description: MR perfusion scan before and during surgery.
Study: NCT03781687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ESP Block
Description: Bilateral ESP Block will be performed at T8
Study: NCT03458650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets
Study: NCT02346253

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo high-dose-rate brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00630344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study: NCT01939327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide/Rituximab
Study: NCT02774369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Individualized aerobic intervention program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Psychological intervention combining behavioral, cognitive, and educational strategies
Study: NCT04240158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6463
Description: IW-6463 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo Tablet
Study: NCT00118742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1-1.5 g orally or intravenously twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil [CellCept]
Description: 1-1.5 g orally or intravenously twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: As prescribed, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: As prescribed, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: 2-4 mg orally once daily for 9-11 months
Study: NCT02575170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino acid solution
Description: a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's lactate solution
Description: 200 ml of Ringer's lactate solution
Study: NCT04602442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 1 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 2 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Study: NCT03853863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-school walking training with minimalist shoes
Description: Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-school walking training with protective shoes
Description: Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
Study: NCT01235234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CF101
Description: orally q12h
Study: NCT03406013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Receive written information on diet and exercise relevant to older men with prostate cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Information
Description: Receive written information on diet and exercise relevant to older men with prostate cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Information
Description: Receive written information on diet and exercise relevant to older men with prostate cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Information
Description: Receive written information on diet and exercise relevant to older men with prostate cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription
Description: Participants receive tailored exercise prescription and tailored diet recommendations
Study: NCT03781687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral ESP Block
Description: Unilateral ESP Block will be performed at T8 (right side)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study: NCT02250196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPMC 2
Description: received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Study: NCT01271868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IB1001
Study: NCT03542409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2HG Spectroscopy Scan
Description: 2HG spectroscopy scan before and during surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Intraoperative MRI
Description: The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
Study: NCT04097106

Intervention type: DIETARY_SUPPLEMENT
Intervention: Synbiotic
Description: Synbiotic dietary supplement in capsule form

Intervention type: DIETARY_SUPPLEMENT
Intervention: Synbiotic
Description: Synbiotic dietary supplement in capsule form
Study: NCT04076657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brock String Therapy
Description: Oculomotor exercise to improve binocular vision function
Study: NCT03781687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study: NCT00185588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib
Description: Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib
Description: Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib
Description: Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib
Description: Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 850 mg/m2
Study: NCT02680821

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ALL reconstruction (Anterolateral ligament)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ACL revision (Anterior cruciate ligament )
Study: NCT00185588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 850 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 850 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 850 mg/m2
Study: NCT03552380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
Study: NCT03347825

Intervention type: PROCEDURE
Intervention: Robotic-assisted lobectomy using da Vinci Surgical System
Description: Robotic-assisted lobectomy

Intervention type: PROCEDURE
Intervention: VATS (video assisted thoracic surgery)
Description: VATS (video assisted thoracic surgery)
Study: NCT04076657

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
Study: NCT03347825

Intervention type: PROCEDURE
Intervention: Open lobectomy
Description: Open lobectomy
Study: NCT03301545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast-Track to Bariatric Surgery
Description: 30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
Study: NCT02680821

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ACL revision (Anterior cruciate ligament )
Study: NCT01861496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiPlaCis
Description: LiPlaCis IV every 3 weeks on day 1, day 8
Study: NCT04461899

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood test
Description: additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
Study: NCT04225182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation protocol
Description: muscular strengthening protocol with traditional rehabilitation protocol without orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with instrumented Orthosis
Description: 8 weeks of muscular strengthening with the orthosis connected to the phone app associated
Study: NCT03152643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blastocyst-stage embryo transfer
Description: All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleavage-stage embryo transfer
Description: All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
Study: NCT03773354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy group for individuals with somatic symptom disorders
Description: The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.